Study Objective: To examine the association between gestational weight gain (GWG) and interpregnancy weight change (IPWC) in adolescent mothers (younger than 20 years), and to determine if this association differs from adult women (aged 20-35 years).
Design: Retrospective cohort study.
Setting And Participants: We included 3055 adolescents and 17,090 adult women with singleton pregnancies recorded in the Nova Scotia Atlee Perinatal Database with a subsequent pregnancy occurring between 2003 and 2014.
Interventions And Main Outcome Measures: GWG in the first pregnancy was categorized as below, within, or above the current Institute of Medicine recommendations. IPWC was defined as the difference between the prepregnancy weights of the 2 pregnancies. Analyses were adjusted for parity, body mass index in the first pregnancy, and time between pregnancies.
Results: Relative to adolescents with GWG within the recommendations, those who gained below had a 2.7 kg (95% confidence interval [CI], 1.4-3.9) lower mean IPWC whereas those who gained above had a 4.2 kg (95% CI, 3.3-5.1) higher mean IPWC. Smaller differences in IPWC between GWG categories were observed in adult women; relative to those with GWG within the recommendations, adults who gained below had a 1.3 kg (95% CI, 0.9-1.7) lower mean IPWC and those who gained above had a 2.9 kg (95% CI, 2.6-3.2) higher mean IPWC.
Conclusion: Mean IPWC differed across GWG categories and the differences were greater in adolescents than in adult women. This difference should be considered when assessing whether specific GWG recommendations are needed for adolescents.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jpag.2017.02.006 | DOI Listing |
JBMR Plus
February 2025
Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC 3168, Australia.
Quantifying precision error for DXA, peripheral QCT (pQCT), and HR-pQCT is crucial for monitoring longitudinal changes in body composition and musculoskeletal outcomes. Agreement and associations between bone variables assessed using pQCT and second-generation HR-pQCT are unclear. This study aimed to determine the precision of, and agreement and associations between, bone variables assessed via DXA, pQCT, and second-generation HR-pQCT.
View Article and Find Full Text PDFFront Nutr
January 2025
Chair of Epidemiology, University of Augsburg, Augsburg, Germany.
Objective: Monitoring dietary habits is crucial for identifying shortcomings and delineating countermeasures. About 20 years after the last population-based surveys in Bavaria and Germany, dietary habits were assessed to describe the intake distributions and compare these with recommendations at food and nutrient level.
Methods: The 3rd Bavarian Food Consumption Survey (BVS III) was designed as a diet survey representative of adults in Bavaria; from 2021 to 2023, repeated 24-h diet recalls were collected by telephone using the software GloboDiet©.
J Diabetes Metab Disord
June 2025
Food and Beverages Safety Research Center, Urmia University of Medical Sciences, Urmia, Iran.
Objectives: To investigate the association between the Dietary Inflammatory Index (DII) and osteosarcopenia using nationally representative data.
Methods: We utilized data from 1,418 men and women aged ≥ 50 years old participating in Iranian Multicenter Osteoporosis Study (IMOS), a nation-wide, cross-sectional study conducted in 2021. Osteosarcopenia was defined based on standard criteria, considering the presence of both osteopenia/osteoporosis and sarcopenia.
Front Med (Lausanne)
January 2025
Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Background: Hyperuricemia is the underlying condition of gout. Previous studies have indicated that specific strategies may be effective in preventing the progression of hyperuricemia to gout. However, there is a lack of widely applicable methods for identifying high-risk populations for gout.
View Article and Find Full Text PDFFront Med (Lausanne)
January 2025
Department of Respiratory Medicine, Reference Centre for Rare Pulmonary Diseases, APHP, Hôpital Avicenne, INSERM U 1272, Université Sorbonne Paris-Nord, Bobigny, France.
LAM is a rare multi-cystic lung disease for which treatment with sirolimus is indicated in cases of moderate or severe lung disease or declining lung function. The aim of this study was to describe patients treated with sirolimus for LAM and their outcomes. This retrospective observational study was based on data from the French national health insurance data system (SNDS).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!